![]()
|
|
||||||||
J Biol Chem, Vol. 274, Issue 29, 20083-20091, July 16, 1999
§,
,
,
,
§,
§¶¶
From the Departments of
Anesthesiology,
¶ Biochemistry and Molecular Genetics, and
§§ Pathology and the § Center for
Free Radical Biology, University of Alabama at Birmingham, Birmingham,
Alabama 35233, the
Department of Obstetrics and Gynecology,
Emory University, Atlanta, Georgia 30322, the ** Institute of
Biochemistry, Humboldt University, Hessische Strasse 3-4 Berlin,
Germany, and the 
Institute of Pharmacology,
Freie University, Thielalle 69-73 Berlin, Germany
| |
ABSTRACT |
|---|
|
|
|---|
Analysis of purified soybean and rabbit
reticulocyte 15-lipoxygenase (15-LOX) and PA317 cells transfected with
human 15-LOX revealed a rapid rate of linoleate-dependent
nitric oxide (·NO) uptake that coincided with reversible
inhibition of product ((13S)-hydroperoxyoctadecadienoic
acid, or (13S)-HPODE) formation. No reaction of ·NO
(up to 2 µM) with either native (Ered) or
ferric LOXs (0.2 µM) metal centers to form nitrosyl
complexes occurred at these ·NO concentrations. During
HPODE-dependent activation of 15-LOX, there was consumption
of 2 mol of ·NO/mol of 15-LOX. Stopped flow fluorescence
spectroscopy showed that ·NO (2.2 µM) did not
alter the rate or extent of (13S)-HPODE-induced tryptophan
fluorescence quenching associated with 15-LOX activation. Additionally,
·NO does not inhibit the anaerobic peroxidase activity of
15-LOX, inferring that the inhibitory actions of ·NO are due to
reaction with the enzyme-bound lipid peroxyl radical, rather than
impairment of (13S)-HPODE-dependent enzyme
activation. From this, a mechanism of 15-LOX inhibition by ·NO
is proposed whereby reaction of ·NO with
EredLOO· generates Ered and LOONO, which
hydrolyzes to (13S)-HPODE and nitrite
(NO2 Lipoxygenases are a family of ubiquitously expressed non-heme
iron-containing enzymes that oxidize the unsaturated fatty acids arachidonate and linoleate to bioactive hydroperoxides and other metabolites (Scheme 1). For example,
5-LOX1 generates precursors
for leukotrienes, products involved in inflammation and allergic
responses (1). 12-Lipoxygenases, present in vascular endothelium,
smooth muscle cells, platelets, and leukocytes (2, 3), contribute to
vascular cell hypertrophy, proliferation, and hypertensive actions,
while 15-LOX is involved in cell development and differentiation,
particularly in reticulocytes where 15-LOX oxidation of mitochondrial
phospholipids is a trigger for their degradation (2, 4, 5).
). Reactivation of
Ered, considerably slower than dioxygenase activity, is
then required to complete the catalytic cycle and leads to a net
inhibition of rates of (13S)-HPODE formation. This reaction
of ·NO with 15-LOX inhibited ·NO-dependent
activation of soluble guanylate cyclase and consequent cGMP production.
Since accelerated ·NO production, enhanced 15-LOX gene
expression, and 15-LOX product formation occurs in diverse inflammatory
conditions, these observations indicate that reactions of ·NO
with lipoxygenase peroxyl radical intermediates will result in
modulation of both ·NO bioavailability and rates of production
of lipid signaling mediators.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

View larger version (11K):
[in a new window]
Scheme 1.
Dioxygenase cycle of 15-LOX. Ferrous enzyme
(Ered) is oxidized by peroxide product
(LOOH), forming ferric enzyme with bound hydroperoxide
product (Eox). Lipid substrate (LH)
binds Eox, becoming oxidized to yield reduced enzyme with
bound lipid alkyl radical (EredL·).
Following rearrangement of the alkyl radical to a conjugated diene,
oxygen is stererospecifically inserted, forming reduced enzyme with
bound lipid peroxyl radical (EredLOO·).
Following reduction of the peroxyl radical by the reduced enzyme, the
ferric enzyme is regenerated (EoxLOOH), and the
peroxide product (LOOH) dissociates. During dioxygenase
turnover, rabbit but not soybean 15-LOX self-inactivates
(Ei).
A central pathogenic role for 15-LOX in atherosclerosis comes from multiple lines of evidence, in particular the co-localization of 15-LOX mRNA, enzymatic activity, and the relatively specific pattern of isomeric 15-LOX oxygenation products that have been detected in early human and rabbit lesions (6-9). The accumulation and oxidation of low density lipoprotein (LDL) lipids by monocytes and the subsequent accumulation of oxidized lipids and foam cells in the vascular intima is a hallmark of early atherogenesis. In vitro studies have shown that macrophage and endothelial cell lipoxygenases readily oxidize externally added LDL and promote metal-dependent lipoprotein oxidation (10-12). In vivo models show that somatic gene transfer of 15-LOX to vessels and transgenic mice cross-bred with LDL receptor-deficient mice results in increased oxidation of LDL and accumulation of lipid-containing vascular lesions (13, 14). A currently provocative counterpoint to these properties of 15-LOX is the observation that targeted overexpression of rabbit macrophage 15-LOX prevented diet-induced atherosclerosis (15). In contrast, diet-induced atherosclerosis in rabbits is inhibited by administration of a 15-LOX inhibitor having limited direct antioxidant properties (16). In aggregate, these observations encourage better understanding of the interactions of 15-LOX, 15-LOX products, and vascular cells with key mediators of vascular function and atherogenesis, in particular ·NO.
In vitro, ·NO can act as a potent antioxidant by
scavenging lipid-derived peroxyl and alkoxyl radicals formed in
purified or LDL lipids oxidized by Cu2+, azo initiators,
peroxynitrite (ONOO
), endothelial cells or macrophages
(17-24). Inhibition of both plant and mammalian
15-LOX-dependent lipid oxidation by high concentrations of
nitric oxide (·NO) was ascribed to formation of an
enzyme-nitrosyl complex (25-27). Nitric oxide can form a nitrosyl
complex with the active site of 15-LOX, a single six-coordinate ferrous
iron liganded to nitrogen and/or oxygen atoms (28), that is detectable
by electron paramagnetic resonance spectroscopy (EPR). The spectrum of
the soybean 15-LOX Fe2+-·NO complex contains two
species, the first attributed to either high spin ferric iron, formed
by transfer of an electron from Fe2+ to ·NO, or an
S = 3/2 system resulting from antiferromagnetic coupling of axial
(D > E) high spin ferrous iron to ·NO (29-31). The
dissociation constant (Kd) for formation of this
species is 95 µM for soybean 15-LOX at pH 7 (31). The second component of the EPR spectra has been suggested to be a high
spin Fe2+-·NO complex and requires ·NO
concentrations of at least 400 µM for detection (30).
Three lines of evidence suggested that oxidation of the reduced iron by
·NO, leading to enzyme activation, might occur following
formation of the nitrosyl complex. Addition of ·NO to anaerobic
ferrous 15-LOX resulted in immediate appearance of a pale yellow color,
identical to that of the ferric enzyme found on treating native enzyme
with HPODE (29). Additionally, EPR and x-ray absorption analysis of
rabbit 15-LOX showed that incubation with millimolar concentrations of
·NO yielded ferric iron species (25). Importantly, the
·NO concentrations required for formation of the
Fe2+-·NO complex significantly exceed those
(a) required to inhibit soybean 15-LOX catalytic activity
(32) and (b) maximal ·NO levels typically found in
biological systems, typically <1-5 µM (33-34),
suggesting that 15-LOX inhibition does not involve Fe2+-·NO complex formation. Thus, other mechanisms
are likely to be operative in the ·NO-mediated inhibition of
lipoxygenase-dependent lipid oxidation.
In addition to the ferrous iron, several species form during 15-LOX catalysis that could potentially react with ·NO and lead to enzyme inhibition. These include enzyme-bound lipid peroxyl, alkoxyl, and carbon-centered radicals. Termination reactions of ·NO with non-lipid-derived radicals are fast, occurring at essentially diffusion-limited rates (35, 36). In addition, kinetic studies indicate that ·NO also reacts extremely rapidly with lipid-derived radicals in aqueous systems (18, 22, 36). Since ·NO can diffuse into the 15-LOX active site, we hypothesized that enzyme-bound lipid-derived radicals are accessible to ·NO during turnover.
In biological systems, efficient removal of ·NO following its
synthesis by nitric oxide synthases is critical in maintaining control
of vascular tone. While oxyhemoglobin, present in erythrocytes, reacts
with and removes ·NO in the vascular space (37), little is known
regarding the processes that remove ·NO in the subendothelial
compartment. The half-life of ·NO in hemoglobin-free cascade
bioassays is only 3-5 s (38), far too short to be accounted for by
simple autoxidation, suggesting that cell-dependent
·NO consumption also occurs. Under pathological conditions
·NO consumption becomes excessive, with complete loss of the
pathways dependent upon activation of soluble guanylate cyclase (39). One component of the inhibition of the ·NO signaling is the
reaction of endothelial-derived relaxation factor with superoxide
(O
2) to yield peroxynitrite (ONOO
) (39-42).
Since reactions of O
2 do not account for complete loss of
·NO signaling to smooth muscle cells (42), other unidentified metabolic pathways that contribute to ·NO consumption are
inferred. Such an alternative are the free radical intermediates
populated during the turnover of enzymes mediating electron transfer
reactions. During development of diet-induced atherosclerosis in
rabbits, impairment of the vascular response to endothelial-derived
relaxation factor or ·NO is a consistent finding (40-42). Since
15-LOX is known to be present in the subendothelial layer in
atherosclerotic lesions and ·NO can concentrate in lipophilic
milieu (33), it was of interest to investigate whether reactions of
lipid radicals generated by 15-LOX can proceed at a significant enough
rate to alter cellular ·NO levels and impact on
·NO-dependent signaling.
Herein, the reactions of soybean and mammalian 15-LOX with ·NO
at concentrations encompassing those found under physiological and
pathological conditions were examined. Our results indicate that there
are two distinct sites for ·NO reaction during 15-LOX catalysis,
and that ·NO consumption occurs during inhibition of 15-LOX. It
was also observed that, during 15-LOX catalysis of lipid oxidation,
lipid radical reactions with ·NO in turn inhibited
·NO-mediated activation of soluble guanylate cyclase and the
subsequent formation of cGMP. In aggregate, these observations reveal
that lipoxygenase reactions with ·NO can inhibit both
lipoxygenase catalytic activity and ·NO-dependent
signal transduction.
| |
EXPERIMENTAL PROCEDURES |
|---|
|
|
|---|
Materials-- Rabbit reticulocyte 15-LOX was purified to electrophoretic homogeneity from the lysate of a reticulocyte-rich blood cell suspension by fractionated ammonium sulfate precipitation and two consecutive steps of fast liquid protein chromatography (43). Soluble guanylyl cyclase was purified from bovine lung to homogeneity by immunoaffinity chromatography as previously (29) Linoleic acid was from Nu-Chek Prep (Elysian, MN). Unless stated otherwise, all enzymes and chemicals, including soybean 15-LOX type V was purchased from Sigma.
Culture of 15-LOX-transfected PA317 Cells--
Murine PA317
fibroblasts stably transfected with either pLLORNL or pLZRNL (44) were
maintained in Dulbecco's modified Eagle's medium supplemented with
10% fetal bovine serum supplemented with glutamine and antibiotics.
The plasmids pLLORNL and pLZRNL are derived from the retroviral vector,
pLDRNL, where the LDL receptor cDNA sequence has been replaced with
either human 15-LOX cDNA or
-galactosidase cDNA (lacZ),
respectively (44, 45). The 15-LOX transfectants are designated clone 12 and have been derived by clonal selection of the pLLORNL-transfected
cells, and possess 10-20-fold greater 15-LOX specific activity than
the lacZ-infected controls (43).
Synthesis of (13S)-Hydroperoxyoctadecadienoic acid ((13S)-HPODE)-- (13S)-Hydroperoxyoctadecadienoic acid ((13S)-HPODE) was synthesized as described (46). Product analysis using both normal and chiral phase HPLC (see "HPLC Analysis of Reaction Products" for details) indicated HPODE products were 97% (13S)-HPODE and 3% (13R)-HPODE.
15-LOX Assay Systems--
To accurately determine enzyme
concentrations, titrations with (13S)-HPODE were monitored
fluorimetrically, where quenching of intrinsic tryptophan fluorescence
during activation is mediated by 1 mol of HPODE/mol of enzyme (47).
15-LOX activity was assayed spectrophotometrically at 234 for
conjugated diene formation (E234 nm = 28 mM
1 cm
1). 15-LOX assay was
performed at 20 °C or 37 °C for the soybean and rabbit enzymes,
respectively, with stirring. The assay mixture was 2 ml 0.1 M potassium phosphate buffer (pH 7.4), 0.5 mM
linoleic acid, 100 mM diethylenetriaminepentaacetic acid
(DTPA), and 0.2% sodium cholate (48). 15-LOX-catalyzed hydroperoxidase
activity was determined as oxodiene formation at 280 nm.
Measurement of Nitric Oxide Uptake--
Anaerobic solutions of
1.9 mM ·NO were prepared by equilibrating ·NO
gas (Matheson, Madison, WI) in argon-saturated deionized water. Any
·NO2 present was eliminated by first bubbling
·NO through 5 M NaOH. Nitric oxide was measured by
electrochemical detection using a ·NO sensor (Iso-NO, WPI Inc.,
Sarasota, FL). Electrode response calibration was done by measuring
·NO liberated from 50 µM KNO2, 0.1 M KI, and 0.1 M H2SO4,
using the following reaction performed under anaerobic conditions:
2KNO2 + 2KI + 2H2SO4
2NO + I2 + 2H2O + 2K2SO4 (as
per the instruction manual). For measurement of ·NO consumption
by 15-LOX, ·NO (1-5 µM) was added to sample
buffer containing linoleate without enzyme. Once the electrode response
had stabilized, enzyme was added and rates of ·NO consumption
recorded. For measurement of ·NO consumption by PA317 cells,
monolayers were trypsinized, washed, counted, then kept at 5 °C in
PBS, pH 7.4. For assay, 1-2 × 106 cells were added
to 1 ml of PBS in the chamber of the ·NO electrode, at 37 °C
with stirring. Nitric oxide (1.9 µM) was added and
consumption rates monitored with or without addition of 0.5 mM linoleate. In some experiments, cells were preincubated with 100 µM eicosatetraynoic acid (ETYA) for 10 min at
37 °C before addition of ·NO and linoleate. Fatty acids were
added in ethanol with final concentration less than 0.5%.
Measurement of Soluble Guanylate Cyclase
Activation--
Guanylate cyclase activity was measured by conversion
of [
-32P]GTP to [
-32P]cGMP at
37 °C for 1 min. Reaction mixtures contained 92 ng of soluble
guanylate cyclase, 3 mM MgCl2, 1 mM
cGMP, 0.3 mM [
-32P]GTP (~3 × 105 cpm) in 0.1 ml of 50 mM triethenolamine/HCl
buffer, pH 7.4. In some reactions, samples also contained 5 µM arachidonate and/or rabbit 15-LOX (1.3 nM). Reactions were initiated by adding DEA-NONOate (0.5 µM) and transferring complete reaction systems from
4 °C to 37 °C. In some reactions, 15-LOX was added at the same
time as DEA-NONOate. Reactions were terminated by ZnCO3
precipitation, followed by isolation of [
-32P]cGMP as
previously (49). Results were corrected for enzyme-deficient blanks and
recovery of cGMP.
Sample Preparation for Analysis of Lipid Oxidation and Nitration Products-- In these experiments, 0.1 mM linoleic acid was used to ensure that lipid substrate was consumed before oxygen was depleted, thus preventing anaerobic hydroperoxidase activity. Nitric oxide (7.6 µM) was added to 0.1 mM linoleate, 100 µM DTPA, and 0.2% sodium cholate, pH 7.4, in 2 ml of phosphate buffer. Then soybean LOX was added, and ·NO consumption rates monitored. As ·NO approached zero, further 7.6 µM additions were made. When all linoleate was consumed, ·NO uptake slowed and samples were immediately removed and placed on ice until extraction of lipids for HPLC analysis. Controls were prepared by allowing 15-LOX to oxidize 100 µM linoleate in the absence of ·NO.
Leukomethylene Blue Assay for Hydroperoxides-- Sample (50 µl) was added to 100 µl of leukomethylene blue reagent (5 mg of leukomethylene blue, 8 ml of dimethylformamide, 1.4 g of Triton X-100, 5.5 mg of hemoglobin in 100 ml of 0.05 M potassium phosphate buffer, pH 5.0) and absorbance measured at 650 nm using a microplate reader (50).
HPLC Analysis of Reaction Products--
Contaminating
NO2
was removed by adding equal
volumes of 1% sulfanilamide, 3 N HCl, and 0.02%
N-(1-napthyl)-ethylenediamine to samples. Following this,
lipids were twice-extracted with two volumes of diethyl ether. Extracts
were dried over sodium sulfate (30 min, 4 °C) and the solvent
evaporated with a stream of nitrogen. Lipids were reconstituted in 0.2 ml of methanol and stored at
80 °C under nitrogen atmosphere.
Reversed-phase HPLC was carried out on a 150 mm × 4.6 mm,
i.e. 5-µm C18 column (Microsorb, Rainin, MA)
using a gradient of 50% B to 90% B over 20 min (A:
water:acetonitrile:acetic acid, 75:25:0.1, v/v; B:
methanol:acetonitrile:acetic acid, 60:40:0.1, v/v) at 1 ml/min.
Absorbance was monitored at 235 nm (conjugated dienes) and 205 nm
(linoleic acid). Products were identified and quantified using
(13S)-HPODE, with standard curves linear over the
concentration range examined, and between-day variation at 6%. Normal
phase high pressure liquid chromatography (NP-HPLC) was carried out on
a Spherisorb S5W column (Phase-Sep 250 × 4.6 mm, 5-µm particle
size) eluted with n-hexane:2-propanol:acetic acid, 100:2:0.1, v/v at 1 ml/min. For determination of HPODE enantiomer composition, a Chiralcel
OD column (J.T. Baker, 250 × 4.6 mm, 5-µm particle size) was
used with n-hexane:2-propanol:acetic acid, 100:2:0.1, v/v,
at 1 ml/min.
Liquid Chromatography-Mass Spectrometry-- To examine for nitrated lipids, mass spectroscopic analyses were performed on an API III triple quadrupole mass spectrometer (PE-Sciex, Concord, Ontario, Canada) following reversed-phase HPLC as described previously (24, 32).
Rapid Kinetic Stopped Flow Measurements of (13S)-HPODE-induced
15-LOX Fluorescence Quenching--
As an index of activation, the rate
and extent of intrinsic tryptophan fluorescence quenching by
(13S)-HPODE was monitored with and without ·NO.
(13S)-HPODE stock (14 µM) was prepared in 2 ml
of 0.1 M potassium phosphate buffer, pH 7.4, with 0.2%
cholate and 100 µM DTPA. Soybean 15-LOX was diluted to
1.76 µM in 0.1 M potassium phosphate buffer, pH 7.4, containing 100 µM DTPA, immediately prior to use.
The HPODE and 15-LOX solutions were placed in separate drive syringes for assay, and equal volumes were mixed during each measurement. Rapid
kinetic stopped-flow studies were carried out on a Hi-Tech SF-53
stopped flow spectrophotometer with a dead time of 1.2 ms. Changes in
fluorescence emission above 320 nm were monitored using a cut-off
filter, with excitation at 280 nm. Nitric oxide was added to HPODE
solution with a final concentration 5.4 µM and immediately placed into the drive syringe for assay.
| |
RESULTS |
|---|
|
|
|---|
Characterization of ·NO Loss in Reaction
Systems--
Nitric oxide (1.9 µM) decay in 1 ml of
aerobic phosphate buffer followed first order kinetics with a rate
constant (kobs) of 4.1 ± 0.6 × 10
3 s
1. Aerobic oxidation of ·NO
follows second order kinetics (51), but at the low ·NO
concentrations utilized in this study the rate of ·NO
autoxidation is slow and alternative reactions that follow first order
kinetics predominate (e.g. ·NO-electrode reaction,
diffusion into gas phase). Using the calculated kobs, the rate of background ·NO loss can
therefore be calculated at any point during the time course.
Cells Transfected with Human 15-LOX Consume ·NO during
Linoleate Oxidation--
Rates of ·NO decay were higher than in
buffer alone when added to murine fibroblast PA317 cells expressing
either 15-LOX or
-galactosidase (controls) and no longer followed
first order kinetics (Fig.
1A). For example, at 1 µM ·NO, the rate of decay is 0.25 µM
min
1 in buffer alone, or 0.64 ± 0.08 µM min
1 and 0.61 ± 0.07 µM min
1 (mean ± S.D.,
n = 3) for 1.7 × 106 15-LOX
transfectants and
-galactosidase controls, respectively (Fig. 1,
A and B). This indicates that
cell-dependent ·NO consuming reactions are taking
place. Addition of linoleate (200-500 µM) induced a
4.8-fold increase in the rate of 15-LOX transfectant-dependent ·NO consumption (2.9 ± 0.2 µM min
1, or 1.7 ± 0.11 nmol
min
1 106 cells
1, mean ± S.D., n = 3) (Fig. 1, A and B)
and had no effect on ·NO consumption by
-galactosidase
transfectants. The linoleate-stimulated ·NO consumption was
completely inhibited by preincubating 15-LOX transfectants with 100 µM ETYA for 10 min at 37 °C before linoleate addition
(Fig. 1C), indicating that ·NO uptake was occurring
as a result of 15-LOX turnover. Under these conditions, there was no
significant injury in the different cell treatment groups, as indicated
by analysis of extents of cell lysis and quantitation of both cell and
medium GSH and GSSG content (data not shown).
|
Nitric Oxide Reversibly Inhibits Purified Soybean and Rabbit
15-LOX--
Addition of 1-6 µM ·NO to rabbit
15-LOX during turnover immediately inhibited conjugated diene
formation. For example, with 1.9 µM ·NO, activity
was inhibited 80% (Fig. 2A).
If ·NO was added before 15-LOX, inhibition appeared as a
prolongation of the lag phase (Fig. 2A). With the soybean
15-LOX, there was less inhibition than with the rabbit 15-LOX (Fig.
2B). For example, when 1.9 µM ·NO was
added during turnover, only 40% inhibition occurred.
|
For both rabbit and soybean 15-LOX, inhibition was reversible, with
time of inhibition directly related to the concentration of added
·NO. Since soybean 15-LOX does not self-inactivate, full
recovery of activity was observed following the inhibition phase.
Plotting the time of inhibition versus ·NO
concentration for the rabbit 15-LOX yielded a linear relationship with
similar slopes, independent of whether ·NO was added to samples
before 15-LOX (m = 14.7 s
µM
1, r = 0.97), or after,
during dioxygenase turnover (m = 14.9 s µM
1, r = 0.98) (Fig.
3).
|
Nitric Oxide Is Consumed during 15-LOX Turnover--
Rates of
·NO consumption by both the rabbit and soybean 15-LOXs were
examined in the presence of linoleate (Table
I, Fig. 4).
No uptake of ·NO occurred in the absence of linoleate, or if
linoleate was replaced with the 15-LOX product (13S)-HPODE
(Fig. 4, A and B). Addition of 750 units/ml CuZn
superoxide dismutase to 15-LOX plus linoleate did not affect rates of
·NO consumption, indicating that superoxide (O
2) was
not the species reacting with ·NO (data not shown). The rates of
·NO consumption directly paralleled inhibition of 15-LOX
activity. The apparent Km for ·NO consumption
was 1.7 ± 0.48 µM for the soybean 15-LOX (Fig. 4C). Since 15-LOX concentrations are 102 to
103 times lower than ·NO (13 nM rabbit
15-LOX, 3.5 nM soybean 15-LOX, 1.9 µM
·NO), it is concluded that ·NO consumption is a catalytic
process requiring dioxygenase turnover.
|
|
Effect of ·NO on Anaerobic Peroxidase Activity--
To
probe the mechanism of 15-LOX inhibition and ·NO uptake, effects
of ·NO on anaerobic peroxidase activity were examined (Scheme
2). Since soybean 15-LOX does not
self-inactivate, anaerobic peroxidase can be measured by allowing the
enzyme to oxidize linoleic acid until all O2 is consumed.
At this point, peroxidase activity initiates and can be monitored by
measuring oxodiene formation. Sequential additions of 1.9 µM ·NO had no effect on anaerobic peroxidase
activity, with base-line irregularities at the point of ·NO
addition being due to opening/closing the sample chamber (Fig. 5).
|
|
Effect of ·NO (13S)-HPODE-induced Fluorescence
Quenching--
Fluorescence quenching of intrinsic tryptophan
fluorescence by (13S)-HPODE is associated with 15-LOX
activation and conversion from ferrous to ferric oxidation state (47,
52). Rapid kinetic stopped flow fluorescence studies were carried out
using soybean 15-LOX, since large amounts of enzyme were required. No
effect of ·NO on the rate or extent of (13S)-HPODE
fluorescence quenching was observed (Fig.
6).
|
Nitric Oxide Consumption during 15-Lipoxygenase
Activation--
High concentrations of native
rabbit or soybean LOX did not consume ·NO in the absence of
substrate (Fig. 7, A and
B). Addition of equivalent amounts of bovine serum albumin
shows that the small decrease in ·NO concentration on addition
of 15-LOX alone was due to dilution or nonspecific effects of adding
protein (Fig. 7A). However, addition of
(13S)-HPODE to 15-LOX-containing samples resulted in
·NO consumption (Fig. 7, A and B).
Plotting ·NO uptake versus enzyme concentration
demonstrated a linear relationship (m = 0.51 ± 0.03, r = 0.99), with the amount of ·NO consumed
being approximately 2 molar eq/mol of 15-LOX (Fig. 7C). HPLC
analysis showed that, during activation of 15-LOX by HPODE, ·NO
did not induce HPODE loss (data not shown).
|
To examine if ·NO activates 15-LOX, the characteristic lag phase
of 15-LOX dioxygenase activity was examined following preincubation with ·NO. Soybean 15-LOX (4 nM) was incubated for 15 min at 25 °C with 3.8 µM ·NO before addition of
linoleate. By the end, 95% of the added ·NO would have been
oxidized to NO2
, ensuring that
residual ·NO was insufficient to inhibit dioxygenase activity.
This preincubation with ·NO had no effect on the time of the lag
(data not shown), indicating that ·NO was not activating
15-LOX.
Fate of Linoleic Acid Oxidized by 15-LOX in the Presence of
·NO--
To determine the fate of linoleate oxidized by 15-LOX
in the presence of ·NO, lipid products were analyzed by HPLC.
Using soybean 15-LOX, a fixed amount of substrate could be completely
oxidized (100 µM) in the presence or absence of
·NO and the yield of products compared. Due to concurrent 15-LOX inhibition by ·NO, the times for complete linoleate oxidation
approximately doubled. For organic solvent extraction of free linoleate
and its oxidation products, acidic conditions maximized yield. However,
small amounts of NO2
, present as a
decomposition product of ·NO, will nitrate lipid hydroperoxides
at low pH, thus depleting LOOH and yielding L(O)NO2 (53).
To avoid this artifact during extraction of 15-LOX products,
contaminating NO2
was first removed by
reaction with sulfanilamide/HCl and
N-(1-napthyl)ethylenediamine. Control experiments determined
that this completely protects LOOH from nitration by acidified
NO2
(data not shown). By both reverse
phase HPLC and quantitation of total hydroperoxide yields, the
predominant product was HPODE (Fig. 8,
A and B). No difference in HPODE yield occurred
if ·NO was present during dioxygenase turnover. Analysis by
normal phase and chiral phase HPLC showed that the HPODE was
predominantly the (13S) isomer (Fig. 8C).
Electrospray mass spectrometry revealed no nitrogen-containing oxidized
lipid species (data not shown), indicating that the product profile of
15-LOX is unchanged by ·NO.
|
The Influence of 15-LOX Catalytic Activity on
·NO-dependent Activation of Soluble Guanylate
Cyclase--
Addition of the ·NO donor DEA-NONOate, in a
concentration that yielded ~400 nM ·NO in the
absence of 15-LOX-mediated peroxyl radical formation, activated soluble
guanylate cyclase formation of cGMP from GTP. Addition of 15-LOX alone
had no effect on extents of cGMP formation unless substrate (5 µM arachidonate) was added, whereupon there was an
extensive and significant 82% decrease in soluble guanylate cyclase
activity and cGMP formation (Fig. 9).
Since fatty acids may inhibit soluble guanylate cyclase, control
experiments were performed to reveal effects of native and oxidized
arachidonate on extents of cGMP formation. 15-Lipoxygenase oxidation of
5 µM arachidonate was allowed to go to completion, prior
to addition to reaction systems containing soluble guanylate cyclase,
[
-32P]GTP, and DEA-NONOate. Soluble guanylate cyclase
was not significantly inhibited by either native or oxidized
arachidonate (data not shown). This affirmed that ·NO reaction
with and consumption by enzyme-bound peroxyl radical intermediates
during catalytic cycling of 15-LOX turnover was responsible for
inhibition of guanylate cyclase, rather than direct guanylate cyclase
inactivation by oxidized lipid products that are formed during 15-LOX
oxidation of arachidonate.
|
| |
DISCUSSION |
|---|
|
|
|---|
These results show that the vascular signal transduction actions
of both ·NO and lipoxygenase products can be interdependent,
since ·NO inhibits rates of 15-LOX product formation and, in
turn, 15-LOX catalytic activity consumes ·NO and thus impairs
guanylate cyclase activation. These findings may in part explain the
anti-atherogenic and anti-cell proliferative actions of ·NO that
have been observed in animal models following L-arginine feeding, administration of ·NO synthase inhibitors, or
transfection with nitric-oxide synthase (54-57). The experiments
reported herein were designed to model mechanisms of ·NO
interactions with lipoxygenase-mediated lipid oxidation and to reflect
conditions that exist in the vascular compartment. For example, the
expression of 15-LOX by cells stably transfected with the human 15-LOX
gene is approximately the same as mouse peritoneal macrophages (44);
thus, the observed cell 15-LOX -dependent rates of
·NO consumption are well within those to be expected
physiologically (~0.85 nmol min
1 106
cells
1; Fig. 1). Maximal rates of
NO2
/
NO3
production in activated rat
peritoneal macrophages or murine RAW264.7 macrophages are 0.1 and 0.2 nmol min
1 106 cells
1,
respectively (58, 59), much lower than the rates of ·NO
consumption observed here. Therefore, it would be expected that the
range of 15-LOX expression in normal and diseased vasculature would
have a significant effect on ·NO available for soluble guanylyl
cyclase activation and cell-mediated host defenses. This was confirmed
by the observation that ·NO-activated soluble guanylate cyclase
formation of cGMP was profoundly suppressed during the catalytic
oxidation of arachidonate by 15-LOX.
To define the mechanism(s) of ·NO reaction with and consumption by 15-LOX, studies were carried out using purified rabbit reticulocyte and soybean 15-LOX. For both enzymes, reversible inhibition was observed on addition of 1-6 µM ·NO (Fig. 2). Inhibition coincided with ·NO consumption, and activity was recovered once ·NO was depleted. For ·NO consumption, addition of linoleate but not (13S)-HPODE was required (Fig. 4) and ·NO consumption was catalytic. These data suggest that an intermediate or product of the dioxygenase cycle react with ·NO to inhibit 15-LOX.
The 15-LOX intermediates that may react with ·NO are shown in Scheme 1. Since linoleate was required (Fig. 4), the oxidized enzyme (Eox), containing Fe3+, is unlikely be the site of ·NO consumption. Another possible reaction site is EredL·. However, since ·NO had no effect on anaerobic peroxidase activity (Fig. 5), a role for this species in ·NO consumption is unlikely. In addition, the low concentrations of ·NO used in these experiments are unlikely to compete efficiently with O2, initially present at 240 µM, for reaction with L· bound at the active site. Finally, the observation that (13S)-HPODE was the major product indicated that ·NO addition occurs after stereospecific O2 insertion has taken place.
Native 15-LOX contains reduced iron and is inactive until oxidized by the product, (13S)-HPODE. During dioxygenase turnover, this results in a characteristic lag phase that can be abolished by prior addition of a small amount of product. At high concentrations of ·NO, a nitrosyl complex forms with the reduced ferrous iron of 15-LOX (29-31). It is therefore possible that ·NO could compete with (13S)-HPODE for reaction with reduced 15-LOX iron. However, using stopped flow fluorescence, no effect of ·NO on either the rate or extent of 15-LOX intrinsic tryptophan fluorescence quenching was found (Fig. 6) (47, 52). Additionally, native 15-LOX did not consume ·NO (Fig. 7) and the time of ·NO inhibition was independent of (13S)-HPODE concentration (Fig. 3). It was recently shown and confirmed herein, that ·NO prolongs the lag phase of 15-LOX activity (Fig. 4, Ref. 25). Inhibition of 15-LOX did not require addition of ·NO before substrate, since the length of ·NO inhibition is the same, whether ·NO was added either before or during enzyme turnover (Fig. 3). This shows that ·NO is not preventing 15-LOX activation and infers that enzyme inhibition results from reaction with a dioxygenase intermediate.
15-LOX did not consume ·NO in the absence of (13S)-HPODE, thus nitrosyl complexes with reduced 15-LOX metal centers did not form. This is not unexpected, since previous studies determined a dissociation constant (Kd = 95 µM at pH 7.0) for the major EPR species formed between ·NO and soybean 15-LOX, far in excess of ·NO concentrations used in this study and those found biologically. A second species was also observed by EPR previous study of ·NO-15-LOX reactions (31). Since formation of this signal required at least 400 µM ·NO, it is also a biologically unlikely explanation of 15-LOX inhibition by ·NO.
Two previous reports suggested that high concentrations of ·NO
could oxidize native 15-LOX, leading to either activation or formation
of a species more susceptible to peroxide activation (25, 29). In both
studies, electron transfer may have occurred following formation of the
iron nitrosyl complex, since it was detectable by EPR spectroscopy.
Herein, low concentrations of ·NO did not activate 15-LOX. The
high Kd for formation of the EPR-detectable
Fe2+-·NO species infers that under physiological
conditions, where ·NO concentrations will be less than 1 µM, both the formation of ferrous-nitrosyl complexes and
activation of 15-LOX by ·NO is unlikely. During activation by
HPODE, consumption of 2 mol of ·NO/mol of 15-LOX was observed.
Reduction of ·NO to NO
by the ferrous iron-derived
electron, followed by secondary reactions of NO
that can
consume ·NO (e.g. HNO + 2·NO
N2O + NO2
,
k = 109 M
1
s
1) may explain these observations.
Since ·NO had no effect on 15-LOX tryptophan fluorescence
quenching, ·NO uptake during activation is also unlikely to
cause enzyme inhibition (Fig. 6). Therefore, ·NO must react at
an additional site during dioxygenase turnover. The only intermediate
that was not excluded experimentally or theoretically is
EredLOO·. Reaction of ·NO with free
LOO· in aqueous solution is extremely fast (k = 1-2 × 109 M
1
s
1; Refs. 15, 19, and 31). Since ·NO can
diffuse into the active site of LOX, as well as concentrate in
lipophilic milieu, a reaction of ·NO with
EredLOO· is highly plausible.
If ·NO reacts with EredLOO· to form LOONO,
dissociation of this product from the active site would leave reduced
enzyme (Ered) that requires reactivation by HPODE for
completion of the catalytic cycle (Scheme
3). Activation of soybean 15-LOX is
approximately 20% of the rate of linoleate dioxygenation (60), while
activation of rabbit 15-LOX is 10% of the rate-limiting step of
dioxygenase activity (0.59 s
1 versus 6.4 s
1, Ref. 61). Therefore, promoting formation of the
inactive enzyme Ered by ·NO reaction with
EredLOO· will significantly decrease the overall
rate of dioxygenase activity and product yield (Scheme 3).
|
The product of reaction between ·NO and LOO·, an organic
peroxynitrite (LOONO), has at least two possible fates in aqueous
conditions. First, it can hydrolyze, forming LOOH and
NO2
. Second, it can decompose
(t1/2 = 0.2-0.6 s, Ref. 36) to form the caged
radicals, [LO· ·NO2]. These either
recombine to form LONO2, an alkyl nitrate, or dissociate to
free species, which can react with additional molecules of ·NO,
forming LONO and NO2
, respectively.
The relative contribution of each of these pathways to LOONO
decomposition is unknown. Since identical amounts of HPODE were formed
either in the presence or absence of ·NO and no LNO2,
LONO2, or LONO was found, hydrolysis of LOONO generated at
the 15-LOX active site to LOOH and NO2
is likely.
A previous report showed that ·NO reaction with soybean 15-LOX
during oxidation of
1-palmitoyl-2-arachidonyl-sn-glycero-3-phosphocholine liposomes as substrate formed LONO2, LNO2,
LOOH(NO2), and LOH(NO2) (32). Herein,
experiments have been designed to ensure that (i) all added ·NO
is consumed through direct reaction with 15-LOX intermediates and (ii)
enzyme turnover did not significantly deplete oxygen, thus avoiding
LOOH decomposition and formation of secondary radicals such as
LO· and L· that can react rapidly with ·NO and
·NO2 to form nitrated products (35, 62, 63).
Finally, treatment of samples with 1% sulfanilamide, 3 N
HCl and 0.02% N-(1-napthyl)-ethylenediamine before
extraction ensured removal of NO2
,
which at low pH will nitrosate LOOH to form nitrated lipids (53).
In summary, our data show that at ·NO and 15-LOX concentrations found in tissues, (a) 15-LOX is inhibited, (b) 15-LOX catalytic activity impairs ·NO-dependent activation of soluble guanylate cyclase, and (c) 15-LOX consumes ·NO through two separate mechanisms. First, during peroxide-mediated activation of 15-LOX, 2 mol of ·NO/mol of 15-LOX are consumed. Second, reaction of ·NO with an intermediate of the dioxygenase cycle, EredLOO·, leads to reversible enzyme inhibition by promoting formation of the inactive ferrous enzyme, Ered. While ·NO reaction during 15-LOX catalysis leads to no change in product profile, significant suppression of HPODE generation occurred in concert with consumption of significant quantities of ·NO.
Since modulation of 15-LOX activity by ·NO occurs at
biologically relevant ·NO concentrations, suppression of HPODE
formation and ·NO consumption is expected in vivo.
The Kd for ·NO activation of soluble guanylyl
cyclase is approximately 250 nM (64); therefore, varying
·NO levels around these concentrations will have significant
impact on cGMP production and resultant smooth muscle relaxation, as revealed in Fig. 9. Thus, consumption of ·NO by the elevated
lipoxygenase activities present in a variety of hypertensive vascular
diseases would then contribute to their characteristic reduced
responses to ·NO (40-42).
| |
FOOTNOTES |
|---|
* This work was supported by National Institutes of Health Grants P60-HL58418, PO1-HL40456, RO1-HL51245 (to B. A. F. and V. D. U.), and R01-HL52628 (to S. P.); by a grant from the Parker B. Francis Foundation (to V. B. O.); and by Deutsche Forschungsgemeinschaft Grant Kn 961/2-2 (to H. K.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
¶¶ To whom all correspondence should be addressed: Dept. of Anesthesiology, 946 THT, 619 19th St. S., University of Alabama at Birmingham, Birmingham, AL 35233. Fax: 205-934-7437; E-mail: bruce.freeman@ccc.uab.edu.
| |
ABBREVIATIONS |
|---|
The abbreviations used are: LOX, lipoxygenase; LDL, low density lipoprotein; HPLC, high performance liquid chromatography; PBS, phosphate-buffered saline; HPODE, hydroperoxyoctadecadienoic acid; ETYA, eicosatetraynoic acid; DTPA, diethylenetriamine pentaacetic acid; DEA-NONOate, 2-(N,N-diethylamino)-diazenolate-2-oxide.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Yamomoto, S., and Smith, W. L. (1995) J. Lipid Med. Cell Signal 12, 195[CrossRef][Medline] [Order article via Infotrieve] |
| 2. | Hamberg, M., and Samuellsson, B. (1974) Proc. N. Y. Acad. Sci. U. S. A. 71, 3400-3404 |
| 3. |
Yokoyama, C.,
Shinjo, F.,
Yoshimoto, T.,
Yamamoto, S.,
Oates, J. A.,
and Brash, A. R.
(1986)
J. Biol. Chem.
261,
16714-16721 |
| 4. | Kühn, H. (1996) Prog. Lipid Res. 35, 203-226[CrossRef][Medline] [Order article via Infotrieve] |
| 5. | Rapoport, S. M., Schewe, T., and Thiele, B. J. (1990) in Blood Cell Biochemistry (Harris, J. R., ed), Vol. 1 , p. 151, Plenum, New York |
| 6. |
Kühn, H.,
Belkner, J.,
Zaiss, S.,
Fährenklemper, T.,
and Wohlfeil, S.
(1994)
J. Exp. Med.
179,
1903-1911 |
| 7. | Yla-Herttuala, S., Rosenfeld, M. E., Parthasarathy, S., Glass, C. K., Sigal, E., Sarkioia, T., Witztum, J. T., and Steinberg, D. (1991) J. Clin. Invest. 87, 1146-1152 |
| 8. | Folcik, V. A., Nivar-Aristy, R. A., Krajewski, L. P., and Cathcart, M. K. (1995) J. Clin. Invest. 96, 504-510 |
| 9. |
Belkner, J.,
Stender, H.,
and Kuhn, H.
(1998)
J. Biol. Chem.
273,
23225-23232 |
| 10. |
Parthasarathy, S.,
Wieland, E.,
and Steinberg, D.
(1989)
Proc. Natl. Acad. Sci. U. S. A.
86,
1046-1050 |
| 11. | Rankin, S. M., Parthasarathy, S., and Steinberg, D. (1991) J. Lipid Res. 32, 449-456[Abstract] |
| 12. | O'Leary, V. J., Graham, A., Stone, D., and Darley-Usmar, V. M. (1996) Free Radical Biol. Med. 20, 525-532[CrossRef][Medline] [Order article via Infotrieve] |
| 13. | Ylä-Herttuala, S., Luoma, J., Viita, H., Hiltunen, T., and Nikkari, T. (1995) J. Clin. Invest. 95, 2692-2698 |
| 14. | Harata, D., Kurihara, H., Levkovitz, H., Shaish, A., and Sigal, E. (1997) Atherosclerosis 134, 279[CrossRef] (abstr.) |
| 15. |
Shen, J.,
Herderick, E.,
Cornhill, J. F.,
Zsigmond, E.,
Kim, H. S.,
Kühn, H.,
Guevara, N. V.,
and Chan, L.
(1998)
J. Clin. Invest.
98,
2201-2208 |
| 16. | Sendobry, S. M., Cornicelli, J. A., Welch, K., Tait, B., Trivedi, B. K., Colbry, N., Dyer, R. D., Feinmark, S. J., and Daugherty, A. (1997) Br. J. Pharmacol. 120, 1199-1206[CrossRef][Medline] [Order article via Infotrieve] |
| 17. | Malo-Ranta, U., Ylä-Herttuala, Metsä-Ketelä, T., Jaakkola, O., Moilanes, E., Vourinen, P, and Nikkari, T. (1994) FEBS Lett. 337, 179-183[CrossRef][Medline] [Order article via Infotrieve] |
| 18. | O'Donnell, V. B., Chumley, P. H., Hogg, N., Bloodsworth, A., Darley-Usmar, V. M., and Freeman, B. A. (1997) Biochemistry 36, 15216-15223[CrossRef][Medline] [Order article via Infotrieve] |
| 19. | Hayashi, K., Noguchi, N., and Niki, E. (1995) FEBS Lett. 370, 37-40[CrossRef][Medline] [Order article via Infotrieve] |
| 20. | Goss, S. P. A., Hogg, N., and Kalyanaraman, B. (1995) Chem. Res. Toxicol. 8, 800-806[CrossRef][Medline] [Order article via Infotrieve] |
| 21. | Jessup, W., Mohr, D., Gieseg, S. P., Dean, R. T., and Stocker, R. (1992) Biochim. Biophys. Acta 1180, 73-82[Medline] [Order article via Infotrieve] |
| 22. | Hogg, N., Kalyanaraman, B., Joseph, J., Struck, A., and Parthasarathy, S. (1993) FEBS Lett. 334, 170-174[CrossRef][Medline] [Order article via Infotrieve] |
| 23. | Yates, M. T., Lambert, L. E., Whitten, J. P., McDonald, I., Mano, M., Ku, G., and Mao, S. J. T. (1992) FEBS Lett. 309, 135-138[CrossRef][Medline] [Order article via Infotrieve] |
| 24. |
Rubbo, H.,
Radi, R.,
Trujillo, M.,
Telleri, R.,
Kalyanaraman, B.,
Barnes, S.,
Kirk, M,
and Freeman, B. A.
(1994)
J. Biol. Chem.
269,
26066-26075 |
| 25. | Weisner, R., Rathmann, J., Holzhütter, H. G., Stöer, R., Mäder, K., Nolting, H., and Kühn, H. (1996) FEBS Lett. 389, 229-232[CrossRef][Medline] [Order article via Infotrieve] |
| 26. | Holzhütter, H. G., Wiesner, R., Rathmann, J., Stöer, R., and Kühn, H. (1997) Eur. J. Biochem. 245, 608-616[Medline] [Order article via Infotrieve] |
| 27. | Kanner, J., Harel, S., and Granit, R. (1992) Lipids 27, 46-49[Medline] [Order article via Infotrieve] |
| 28. | Kuban, R. J., Weisner, R., Rathman, J., Veldink, G., Nolting, H., Sole, V. A., and Kühn, H. (1998) Biochem. J. 332, 237-242 |
| 29. | Galpin, J. R., Veldink, G. A., Vliegenthart, J. F. G., and Boldingh, J. (1978) Biochim. Biophys. Acta 536, 356-362[Medline] [Order article via Infotrieve] |
| 30. | Salerno, J. C., and Siedow, J. N. (1979) Biochim. Biophys. Acta 579, 246-251[Medline] |